The Steno Diabetes Study

Reviewed by K.M. Venkat Narayan, MD, MPH, FRCP, FACP

STUDY

SUMMARY
Objective. A comparison of the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on risk factors for cardiovascular disease (CVD).

Design. Randomized, open, parallel trial at the Steno Diabetes Center in Denmark.

Participants. Eighty patients with type 2 diabetes and microalbuminuria were assigned to receive conventional treatment in accordance with national guidelines, and another 80 were assigned to receive intensive treatment with stepwise implementation of behavior modification and pharmacological therapy that treated hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with aspirin.

Primary endpoints. Death from CVD, nonfatal myocardial infarction (MI), nonfatal stroke, revascularization, and amputation.

Results. At a mean follow-up of 7.8 years, patients receiving the intensive therapy had a 53% (95% CI: 27–76%) lower risk of CVD, 61% (13–83%) lower risk of nephropathy, 58% (14–79%) lower risk of retinopathy, and 63% (21–82%) lower risk of autonomic neuropathy. One CVD event was prevented for every five patients treated intensively for 7.8 years.

Conclusion. A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces risk of CVD and microvascular events by about 50%.

COMMENTARY
People with diabetes have two to three times the risk of CVD than those without diabetes. Effective treatments are available to prevent the macro- and microvascular complications of diabetes. In particular, there is evidence of benefit of single-factor interventions: intensive glucose, lipid, and blood pressure control; treatment of microalbuminuria; and use of regular aspirin. There is, however, scant literature on the effectiveness of multifactorial interventions, as would be applied in clinical practice, on CVD among people with diabetes.

The Steno study has attempted to close this gap in evidence by testing an intensive multifactorial intervention against conventional treatment. The intensive intervention consisted of stepwise introduction of lifestyle and pharmacological therapy that treated hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with aspirin.

Although the study was justified, based on existing evidence for CVD benefit, in including smoking cessation, physical activity promotion, lipid and blood pressure control, aspirin therapy, and ACE inhibitor therapy, strong evidence for microvascular benefits from glycemic control exists, and, although not unequivocally established, glucose control may also have positive benefits on CVD. On the other hand, CVD benefits from routine vitamin or mineral supplementation have not been established, and their inclusion in a multifactorial intervention to prevent CVD is premature.

Despite these limitations, the Steno study provides evidence that an aggressive multifactorial intervention can be delivered in a real-life clinical practice.
situation and can lower the risk of CVD among people with diabetes and microalbuminuria by about 50%. The quality of diabetes care remains suboptimal in the United States and elsewhere, despite the availability of effective treatments to prevent CVD. The Steno study shows us the benefits of multifactorial interventions in practice and gives us strong reason to believe that evidence-based guidelines can be translated into clinical practice. The potential benefit to be accrued, in terms of CVD prevention, from the systematic application of current knowledge is enormous.

REFERENCES


K.M. Venkat Narayan, MD, MPH, FRCP, FACP, is a physician-epidemiologist at the Centers for Disease Control and Prevention and an adjunct professor at Rollins School of Public Health at Emory University in Atlanta, Ga.